Libera Bio® is a biopharma preclinical-stage company spun off from the laboratory of Professor María José Alonso, worldwide leader in Nanomedicine, at the University of Santiago de Compostela (USC), in Northwest Spain. Our purpose is to harness the potential of a proprietary nanotechnology platform for drug delivery (MPN Technology®) with the ambition of creating a next generation of Precision Nanomedicines to radically improve the treatment of cancer. Our lead candidate is a novel nanomedicine (MPN-Anti-KRAS), containing a new monoclonal antibody able to reach specific mutations of the oncoprotein KRAS, so far considered an undruggable intracellular target.
Libera Bio offers one position as Research Scientist supported by “Programa INVESTIGO” (Xunta de Galicia).
